Setiawan Andy, Widodo Agung Dwi Wahyu, Endraswari Pepy Dwi
Study Program of Clinical Microbiology, Universitas Airlangga, Surabaya, Indonesia.
Department of Clinical Microbiology, Universitas Airlangga, Dr. Soetomo General Academic Hospital, Surabaya, Indonesia.
Ann Med Surg (Lond). 2022 Nov 5;84:104841. doi: 10.1016/j.amsu.2022.104841. eCollection 2022 Dec.
Antibiotic resistance is a significant problem in the world, so optimization of antibiotic use is needed. is a Gram-negative bacterium that causes bacteremia, sepsis, UTIs, pneumonia, nosocomial infections and ESBL-producing bacterium. ciprofloxacin, cotrimoxazole, and doxycycline are broad-spectrum antibiotics, including in WHO essential drugs.
The study tested antibiotics that most effectively inhibited non-ESBL, ESBL invitro with analysis.
This experiment used ATCC isolates, stored clinical isolates of non-ESBL, ESBL, and the control group. Isolates other than control were challenged with , , oral preparations with concentrations of 1, 2, 4 MIC at 0, 2, 4, 6, 8, 24 h. At each hour, the bacteria were cultured, incubated, calculated the number of colonies. The results were analyzed with time-kill curve and tested statistics. Statistical analysis used included ANOVA, post-Hoc, Mann Whitney, and Kruskal Willis tests with < 0.05.
, in this study had inhibition effects on non-ESBL and ESBL. had the best inhibitory effect. Statistically, the most meaningful differences of antibiotics in and at four and 24 h ( < 0.001), in concentrations of 1 MIC and 4 MIC at 2 h ( < 0.001), and in ESBL and ATCC at 8 h ( = 0.024).
is the best antibiotic to inhibit the growth of non-ESBL and ESBL compared to and . The inhibitory effect increases with an increase in concentration.
抗生素耐药性是全球一个重大问题,因此需要优化抗生素使用。[细菌名称未给出]是一种革兰氏阴性菌,可引起菌血症、败血症、尿路感染、肺炎、医院感染,并且是产超广谱β-内酰胺酶(ESBL)的细菌。环丙沙星、复方新诺明和强力霉素是广谱抗生素,包括在世界卫生组织基本药物清单中。
本研究通过[分析方法未给出]测试了在体外最有效地抑制非ESBL[细菌名称未给出]和ESBL[细菌名称未给出]的抗生素。
本实验使用了[细菌名称未给出]ATCC菌株、储存的非ESBL[细菌名称未给出]、ESBL[细菌名称未给出]临床分离株以及对照组。除对照组外的分离株分别用浓度为1、2、4倍最低抑菌浓度(MIC)的[抗生素名称未给出]、[抗生素名称未给出]、[抗生素名称未给出]口服制剂在0、2、4、6、8、24小时进行挑战。每小时对细菌进行培养、孵育并计算菌落数。结果采用时间-杀菌曲线分析并进行统计学检验。所使用的统计分析包括方差分析、事后检验、曼-惠特尼检验和克鲁斯卡尔-沃利斯检验,P<0.05。
本研究中的[抗生素名称未给出]、[抗生素名称未给出]对非ESBL[细菌名称未给出]和ESBL[细菌名称未给出]有抑制作用。[抗生素名称未给出]具有最佳抑制效果。在统计学上,抗生素在4小时和24小时时对[细菌名称未给出]和[细菌名称未给出]的最显著差异(P<0.001),在2小时时1倍MIC和4倍MIC浓度下(P<0.001),以及在8小时时对ESBL[细菌名称未给出]和[细菌名称未给出]ATCC(P = 0.024)。
与[抗生素名称未给出]和[抗生素名称未给出]相比,[抗生素名称未给出]是抑制非ESBL[细菌名称未给出]和ESBL[细菌名称未给出]生长的最佳抗生素。抑制作用随浓度增加而增强。